Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CollaGenex's Col-118 meets erythema endpoint

CGPI said the high and middle doses of Col-118 met the primary

Read the full 121 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE